Bacterial Curli Amyloid: Researchers Examine the Role of Bacterial Infection in Lupus Pathology June 3, 2016 • By Richard Quinn

Estándar

Although most research efforts focus on the genetic and environmental factors of systemic lupus erythematosus (SLE), novel new research highlights the effect bacterial infections can have on lupus activation and flares. The article, “Amyloid-DNA Composites of Bacterial Biofilms Stimulate Autoimmunity,” explains how researchers identified the amyloid protein curli, a component of bacterial biofilms, as a trigger for “immune activation and production of autoantibodies in lupus-prone and wild-type mice.”1

“Repeated administration of these curli-DNA actually accelerate the onset of lupus in lupus-prone mice,” says Stefania Gallucci, MD, associate professor and associate chair of the Microbiology and Immunology Department at the Lewis Katz School of Medicine of Temple University in Philadelphia. “For years and years, rheumatologists and immunologists have known there is a connection between infections and lupus. But we still don’t know much about the molecules involved and the mechanisms of infection that affect lupus. We have discovered one molecule—bacterial curli amyloid—that is one of the ways infection can trigger or make lupus [flares] worse.”

Infections are known to be key factors in lupus patient mortality and hospitalization. Better knowledge of biofilms and how they activate the immune system might lead to changes in lupus treatments. And study data suggest clinicians keep an eye out for lupus patients who present with chronic infections, such as urinary tract infections.

The Research Team: Dr. Stefania Gallucci (center) with colleagues Cagla Tukel, MD, (left), a microbiologist and expert in bacterial amyloids, and Roberto Caricchio, MD, a rheumatologist and director of the Lupus Clinic at Temple University School of Medicine in Philadelphia.
The Research Team: Dr. Stefania Gallucci (center) with colleagues Cagla Tukel, MD, (left), a microbiologist and expert in bacterial amyloids, and Roberto Caricchio, MD, a rheumatologist and director of the Lupus Clinic at Temple University School of Medicine in Philadelphia.
“The key thing for practicing rheumatologists,” Dr. Gallucci says, “is to pay attention to infections in lupus patients, not only as an effect of the immunosuppression, but actually as a cause of activation and flare in lupus. Treating the infection can be beneficial for long-term lupus disease.”

Dr. Gallucci notes the contributions to the research of her collaborators, microbiologist Cagla Tukel, PhD, and Roberto Caricchio, MD, of Temple’s Division of Rheumatology. The next step for the team, she says, is to take the work into Dr. Caricchio’s lupus clinic in translational studies.

“This is just the beginning of a new line of research that we want to pursue,” she says.

Richard Quinn is a freelance writer in New Jersey.

Reference

Gallo PM, Rapsinski GJ, Wilson RP, et al. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity. 2015 Jun 16;42(6):1171-84. doi: 10.1016/j.immuni.2015.06.002.

Tabalumab development for lupus stops because of mixed phase III results

Estándar

SEPTEMBER 4, 2015

The injectable investigational biologic tabalumab met its primary endpoint only at higher doses, and failed to meet secondary endpoints in phase III clinical trials for moderate to severe systemic lupus erythematosus. A heterogeneous patient population, intensity of background therapy, and endpoints that set a relatively high bar for efficacy all contributed to the mixed results of the ILLUMINATE-1 and ILLUMINATE-2 trials, according one of the study’s lead authors.

keep reading

Lupus Nephritis. MMF not superior to AZA as maintenance therapy

Estándar

Nature Reviews Rheumatology 11, 258 (2015) doi:10.1038/nrrheum.2015.47
Published online 31 March 2015

The 10-year follow-up data from the MAINTAIN nephritis trial showed that mycophenolate mofetil (MMF) was not superior to azathioprine (AZA) as maintenance therapy for a population of white patients with proliferative lupus nephritis. Survival, kidney function, 24 h proteinuria and renal flares were assessed in 92 of 105 patients originally…